关于新诊断的AML适合和不适合患者的治疗选择
Gray H Magee1, Michael R Grunwald2
1Atrium Health Levine Cancer Institute, 1021 Morehead Medical Drive, LCI Building 2, Charlotte, NC, 28204, USA. Gray.magee@advocatehealth.org.
下一代测序 (NGS) 和向治疗正在彻底改变急性髓性白血病 (AML) 的治疗. 早期分子分析对于AML患者的个性化前线策略至关重要.
科学领域:
- 血液学
- 癌症学
- 遗传学
背景情况:
- 下一代测序 (NGS) 和先进的细胞遗传学正在改变急性髓性白血病 (AML) 的治疗方法.
- 分子造型识别可操作的突变 (例如FLT3,IDH1/2,KMT2A,NPM1) 用于个性化治疗.
研究的目的:
- 根据分子分析和患者健康状况,概述目前急性髓性白血病 (AML) 的前线治疗策略.
- 强调早期分子表征在优化AML治疗选择中的关键作用.
主要方法:
- 将NGS和细胞遗传诊断纳入临床实践.
- 针对性小分子抑制剂和标准化疗方案的使用 (例如,7+3,CPX-351).
- 在不适合治疗的患者中使用低甲基剂和venetoclax.
主要成果:
- 个性化治疗策略可以通过分子分析,指导使用向疗法.
- 根据突变状况和患者特征,使用特定药物,如中素,奎萨丁尼布,吉姆图祖马布臭素,CPX-351和venetoclax组合.
- 新兴的脑膜抑制剂在前线环境中对KMT2A重组或NPM1突变的AML有希望.
结论:
- 及时的分子表征对于选择最佳的AML前线策略至关重要.
- 对于具有特定分子变异的患者,建议参加临床试验.
- 随着治疗环境的不断变化,需要不断调整AML的诊断和治疗方法.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Tumor Immunotherapy
